Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers

M. Montana (1) , C. Ducros (2) , P. Verhaeghe (1) , T. Terme (3) , P. Vanelle (3) , P. Rathelot (3)

1 CBRL - Chimie, biologie et radicaux libres - UMR 6517
2 SIMaP - Science et Ingénierie des Matériaux et Procédés
3 ICR - Institut de Chimie Radicalaire

Paclitaxel and docetaxel are established as the standards of care, either as monotherapy or in combination with other cytotoxic agents in metastasic breast cancer. In order to improve the efficiency of solvent-based paclitaxel and to overcome its drawbacks in terms of safety, a solvent-free formulation has been developed. This work is a review of the albumin-bound paclitaxel data relative to its pharmacodynamic and pharmacokinetic profiles, its therapeutic efficiency and its safety of use. The activity of albumin-bound paclitaxel in phase

Domaines: Chimie

M. Montana, C. Ducros, P. Verhaeghe, T. Terme, P. Vanelle, et al.. Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers. Journal of Chemotherapy, 2011, 23 (2), pp.59--66. ⟨hal-01460327⟩